Skip to main content
. 2019 Feb 18;129(3):1295–1313. doi: 10.1172/JCI124030

Figure 7. VPA treatment mitigates CREB-mediated EGR1 upregulation in primary podocytes treated with LPS or PS.

Figure 7

(A) Representative immunoblots of EGR1 and WT1 in primary podocytes with or without LPS or PS, treated or not treated with VPA or SAHA. (B and C) Quantification of EGR1 immunoblots in primary podocytes with LPS (B) or PS (C) treated or not treated with VPA or SAHA. *P < 0.05 vs. control, #P < 0.05 vs. LPS- or PS-treated primary podocytes; n = 3. (D and E) ChIP assay using CREB antibody and primer sets for Egr1 promoter in primary podocytes with LPS (D) or PS (E) treated or not treated with VPA or SAHA. DNA binding was determined by PCR. *P < 0.05 vs. control, #P < 0.05 vs. LPS- or PS-treated primary podocytes; n = 3. (F) Representative immunoblots of phosphorylated CREB (p-CREB), CREB, and WT1 in LPS- or PS-treated primary podocytes with or without VPA or SAHA. (G and H) Quantification of p-CREB immunoblots in primary podocytes with LPS (G) or PS (H) treated or not treated with VPA or SAHA. *P < 0.05 vs. control, #P < 0.05 vs. LPS- or PS-treated primary podocytes; n = 3. (B–E, G, and H) Statistically analyzed by 1-way ANOVA with Dunnett’s correction.